- Home
- OVBC vs CLLS Comparison
OVBC vs CLLS Comparison
Compare OVBC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVBC
- CLLS
- Stock Information
- Founded
- OVBC 1872
- CLLS 1999
- Country
- OVBC United States
- CLLS France
- Employees
- OVBC N/A
- CLLS N/A
- Industry
- OVBC Major Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- OVBC Finance
- CLLS Health Care
- Exchange
- OVBC Nasdaq
- CLLS Nasdaq
- Market Cap
- OVBC 149.1M
- CLLS 143.4M
- IPO Year
- OVBC N/A
- CLLS 2007
- Fundamental
- Price
- OVBC $34.63
- CLLS $1.59
- Analyst Decision
- OVBC
- CLLS Buy
- Analyst Count
- OVBC 0
- CLLS 1
- Target Price
- OVBC N/A
- CLLS $4.00
- AVG Volume (30 Days)
- OVBC 32.5K
- CLLS 48.2K
- Earning Date
- OVBC 07-25-2025
- CLLS 08-05-2025
- Dividend Yield
- OVBC 2.54%
- CLLS N/A
- EPS Growth
- OVBC 10.90
- CLLS N/A
- EPS
- OVBC 2.67
- CLLS N/A
- Revenue
- OVBC $61,741,000.00
- CLLS $54,747,000.00
- Revenue This Year
- OVBC N/A
- CLLS $48.52
- Revenue Next Year
- OVBC N/A
- CLLS $5.17
- P/E Ratio
- OVBC $12.96
- CLLS N/A
- Revenue Growth
- OVBC 10.84
- CLLS 351.26
- 52 Week Low
- OVBC $20.52
- CLLS $1.10
- 52 Week High
- OVBC $40.99
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- OVBC 63.66
- CLLS 56.98
- Support Level
- OVBC $33.80
- CLLS $1.56
- Resistance Level
- OVBC $35.17
- CLLS $1.49
- Average True Range (ATR)
- OVBC 1.40
- CLLS 0.09
- MACD
- OVBC 0.60
- CLLS 0.01
- Stochastic Oscillator
- OVBC 92.95
- CLLS 80.00
About OVBC Ohio Valley Banc Corp.
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.